Compare Biogen Inc (BIIB) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Invesco WilderHill Clean Energy ETF trades at $34.98. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | PBW | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $46.99 |
52-Week Low | $122.68 | $22.23 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PBW (Invesco WilderHill Clean Energy ETF) trades at $34.00, down 3.46% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while clean energy sector news highlights both volatility and growth potential driven by energy security concerns and data center demand. Recent articles note PBW's 34% year-to-date gains but caution about rate cycle sensitivity.
Outlook remains mixed with technical weakness offset by clean energy tailwinds. Investment opportunity lies in global energy transition trends, but risks include interest rate sensitivity and sector volatility. The ETF's performance is heavily influenced by macroeconomic factors rather than individual company fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
